Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - SECOND SIGHT MEDICAL PRODUCTS INC | s101520_ex99-1.htm |
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): July 22, 2015
| SECOND SIGHT MEDICAL PRODUCTS, INC. | |||||
| (Exact Name of Registrant as Specified in Its Charter) | |||||
| California | |||||
| (State or Other Jurisdiction of Incorporation) | |||||
| 333-198073 | 02-0692322 | ||||
| (Commission File Number) | (IRS Employer Identification No.) | ||||
|
12744 San Fernando Road, Suite 400 |
|||||
| (Address of Principal Executive Offices) | |||||
| (818) 833-5000 | |||||
| (Registrant's Telephone Number, Including Area Code) | |||||
| (Former Name or Former Address, if Changed Since Last Report) | |||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 Other Events
On July 22, 2015, the Company issued a press release announcing the first implant and successful activation of the Argus® II Retinal Prosthesis System in a dry age-related macular degeneration (AMD) patient. The implant, performed at Manchester Royal Eye Hospital in Manchester, England, is part of a groundbreaking study which aims to evaluate the feasibility of the Argus II System in individuals with late stage dry AMD that is severely affecting central vision. Second Sight anticipates implanting up to a total of five patients with the Argus II initially as part of this study to evaluate the feasibility of the device in patients with late stage dry AMD. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by this reference.
ITEM 9.01 Financial Statements and Exhibits
Exhibit No. Description
99.1 Press Release issued July 22, 2015
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 23, 2015
SECOND SIGHT MEDICAL PRODUCTS, INC.
/s/ Thomas B. Miller
By: Thomas B. Miller
Chief Financial Officer
2